



RESULTS OF THE FOURTH QUARTER OF 2018

- INVESTMENT IN CC & C - NEWS FROM OUR RESEARCH PROJECTS

Arles, December 31, 2018 - CELL CONSTRAINT & CANCER, a company specializing in the treatment of pancreatic cancer by mechanical signals, presents its review of the past period, as well as its strategic priorities for the next quarter.

A SUBSTANTIAL STAKE ACQUISITION IN CC & C

TOD Finances, Vendéen family office, should invest 100,000 Euros in the company. The negotiations are in the final phase and should be completed by the end of February 2019. A General Meeting of shareholders is expected to proceed to the capital increase.

Mr. Sidney Ouvrard, manager of TOD Finances, says: "We have an investor dimension, but also a taste for human projects. Finding a solution for cancer patients whose short-term outcome is known is a source of motivation for us. I think we will feel proud to take part in this great adventure. "

It's a pride we share, and great news for our company, whose existence is assured for the next two years. We will be able to focus exclusively on funding our Evidence of Efficiency on public funds and hire an additional researcher to lead ongoing research and set up new projects. This contribution also marks the end of our annual capital increase for individual investors. The next investing round should be done on the occasion of the first results of our experimentation in mice transplanted with pancreatic cancer; we will then turn to Investment Funds, to upscale.

We must thank the 93 shareholders who trusted us and brought CC & C to this new start.

RESEARCH PROJECTS

The resubmission of the FET-Open file, within [NanoStress](#), the European consortium around the INSERM laboratory of Pr. Couvineau, has taken a good part of our energies: to understand the objections of the examiners, to answer them, to re-write. This experiment will allow us to demonstrate the therapeutic efficacy of our method in mice transplanted with human pancreatic cancer. The main objectives of the file remain the same, except that we go from two years of work to three years; budgets will increase accordingly, and we include the design of a prototype for the human being at the end of the animal experiment.

The Magcell project, in collaboration with ICGM and CBS (based in Montpellier), was pre-accepted for funding by the Occitanie Region on December 17th, 2018. It will study the action of a stress field on a group of some human pancreatic cancer cells. The final file must be submitted before March 1st, 2019.

We were approached by the journal [BioMolecules](#) to participate in their next special issue on the therapeutic tracks opened by mechanobiology, in April 2019. This is a signal that Physical Oncology is going awareness. This will probably be an opportunity to publish faster than expected the results of the study of Elsa Bazellières, [our partner of the IBDM Marseilles](#).

FEW BREAKS

CC & C took part in two events: Innov'in Med, on November 19 and 20 in Marseilles, and WeLikeStartups Challenge # 10, on November 27 in Paris. It was an opportunity to make new contacts with start-ups, business angels and representatives of investment funds, and to continue to publicize our project.

We also have applied for [G-Factor](#), an acceleration program led by the Golinelli Foundation in Bologna, which gives each laureate 100,000 Euros and 6 Months of support. Result of the competition in February 2019.

2019: ASSESSMENT AND PROSPECTS

The turning point we have been feeling for a while now should realize with the contribution of TOD Finances. Contacts have been made with prestigious research laboratories around the world, with whom we have developed protocols to demonstrate, with experimentation, the therapeutic efficacy of our method on pancreas cancer. One way or another, we will have to manage to finance these experiments, either through the FET-Open, or by other means. This must be achieved this year to have first results in 2020.

As soon as these results are known, if they are positive, we will start the development of a human prototype, with the help of financial and industrial partners. A new funding round will be necessary. To do so, it will be necessary that TOD Finances and the 93 current shareholders of CC & C conclude a shareholders' pact. This is the second goal of 2019.

Investors are not convinced in two meetings. The third objective of 2019 will be to establish a strategy for the Funds and the Industrialists, to put in place the tools, and to start meeting them for preliminary contacts, in France, in Europe and in the world.

Finally, our Intellectual Property is our main asset. Our patent is under examination in three zones: Europe, United States and Japan. We should get it pretty quickly in one of three areas. It will be necessary to try to accelerate the work on the two other zones, with the help of our IP consultant.

CALENDAR OF THE BEGINNING OF YEAR

- ✓ January: First results of Elsa Bazellières's experimentation at the IBDM (Marseille)
- ✓ January 24th: Deadline for filing the FET-Open (NanoStress) project
- ✓ February: Result of the G-Factor contest
- ✓ End of February: Extraordinary CC & C General Assembly and TOD Finances investment
- ✓ March 1st: Deadline for submission to the Occitanie Region (of the "MagCell" project)
- ✓ April: Publication in BioMolecules
- ✓ End of April: Result of the FET-Open submission
Ordinary CC & C General Assembly
- ✓ Beginning of May: Hiring a researcher

Next appointment: March 31, 2019 - Update on the activity of the 1st quarter of 2019

Find all the information on CELL CONSTRAINT & CANCER:

<http://new.cellconstraintcancer.com/>



About CELL CONSTRAINT & CANCER

Founded in 2009 by Rémy BROSSEL, medical oncologist and physicist, CELL CONSTRAINT & CANCER develops innovative treatments based on [physical oncology](#), complementary to current approaches in oncology. Addressing primarily non-metastatic non-operable tumors, such as cancer of the pancreas, brain, or liver, the company published in May 2016 a proof of concept of slowing the growth of an in vivo grafted cancer tumor, by the action of mechanical signals (read our article: [Mechanical signals inhibit growth of a grafted tumor in vivo: Proof of Concept](#)).

Major partnerships (CNRS, INSERM, Stanford University) and the support of its shareholders since its beginning allow us today to initiate a new phase of experiments on animals intended to provide Proof of Efficacy of this technology on unmet medical needs.

CONTACTS

Press Relations

Barthélémy BROSSEL

Tél. : +33 (0)6 50 22 79 64

Mail : barth.brossel@gmail.com

Shareholders & Investors Relations

Christine GRAU

Tél. : +33 (0)4 90 18 48 50

Mail : investisseurs@cellconstraintcancer.com